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Abstract The activation of p70s6k is accompanied by a complex 
series of phosphorylation events. In this review we propose a 
model of activation which divides p70s6k into four functional 
modules that cooperate in leading to full enzyme activity. In the 
light of the model, we suggest how candidate effectors of p70s8k 
activation might function by directing the phosphorylation of 
specific sites. 
© 1997 Federation of European Biochemical Societies. 
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1. The significance of p70 /p85 in cell cycle progression 
The discovery that mitogen-induced metabolic processes 
maybe regulated by serial phosphorylation and dephosphoryl-
ation events has captivated the attention of signal transduc-
tion scholars for over a decade [1]. The application of this 
finding has motivated workers to purify, clone and crystallise 
many of the proteins responsible for mediating specific mito-
genic events. The goal of this laboratory has been to unravel 
the complex series of signalling events which lead to, and 
from, the activation of the p70/p85 isoforms of S6 kinase, 
p70s6k/p85s6k [2-4]. The p70sfik is recognised as the kinase 
which regulates the multiple phosphorylation of 40S riboso-
mal protein S6 in vivo, distinct from the p21ras-mediated 
p9Qrsk r5] inhibition of mitogen-induced p70s6k/p85s6k activa-
tion in vivo with either neutralising antibodies [6,7] or by 
treatment with the immunosuppressant rapamycin [8-10] se-
verely compromises the ability of the cell to progress through 
the Gl phase of the cell cycle. The importance of these ob-
servations is emphasised by the critical role p70s6k plays, pre-
sumably through S6 phosphorylation, in regulating the trans-
lation of a class of mRNA transcripts which contain an 
oligopyrimidine tract at their transcriptional start site [4]. 
This class of mRNAs encode for many of the components 
of the protein synthetic apparatus and can represent up to 
20% of the total mRNA in the cell [11]. Failure to recruit 
these messages into polysomes suppresses the biogenesis of 
translational machinery required for cell cycle progression 
[12]. 
The p70s6k/p85s6k isoforms are generated from alternative 
translation start sites on the same transcript (Y. Chen and 
S. Kozma, unpublished). The two isoforms are coordinately 
regulated and only differ by a 23 amino acid N-terminal ex-
tension which constitutively targets p85s6k to the nucleus [7]. 
Whilst the mechanism by which p85s8k mediates cell cycle 
progression is, as yet, unresolved, it is noteworthy that S6 is 
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present in a free form in the nucleus and becomes phosphoryl-
ated at the same residues in response to mitogens as its cyto-
plasmic counterpart [13]. As the role of S6 in the cytoplasm 
and nucleus has been recently discussed [4,14], we will con-
centrate here on the upstream signalling elements and the 
modular mechanisms which culminate in p70s6k activation. 
2. The putative signalling components that elevate p70s6k 
activity 
The observation that p70s6k activity could be preserved in 
cell extracts supplemented with phosphatase inhibitors [15,16] 
provided the first indication that mitogen-induced kinase ac-
tivity could be potentiated by a series of phosphorylation 
events (see below). The kinase was subsequently purified 
[16,17] and the cDNA cloned [18,19]. MAPK has been shown 
to directly phosphorylate p70s6k in vitro [20], but studies em-
ploying dominant interfering signalling components or recep-
tor mutants [21] have demonstrated that MAPK is neither 
necessary nor sufficient to elicit p70s6k activation. Indeed, it 
is becoming increasingly evident that p70s6k activation is a 
complex process requiring multiple signalling inputs [22-24] 
and that these inputs are likely to be shared with the p85s6k 
isoform [7,8]. This complexity has led to the utilisation of two 
broad approaches in attempting to elucidate the mechanism of 
activation, with most studies focusing on the p70s6k form. 
One approach, which has been in vogue, is to construct a 
p70s6k signalling pathway by utilising compounds which in-
hibit p70s6k activation [8,9,25-27] although a full understand-
ing of how these molecules achieve this end is lacking. As 
shown in the model (Fig. 1) several signalling components 
have been implicated in the activation of p70s6k. The immu-
nosuppressant rapamycin is the most potent inhibitor of 
p70s6k described, blocking its activation by all known agents 
[8,9,25]. The target of rapamycin, as a gain-of-function inhib-
itory complex with FKBP12, is mTOR/FRAP [28], first iden-
tified in yeast as TOR-l/TOR-2 [29]. Since an mTOR/FRAP 
mutant, which is unable to bind rapamycin-FKBP12, protects 
p70a6k activity in the presence of the inhibitor, it has been 
reasoned that mTOR/FRAP is an upstream regulator of 
p70sf,k [30]. mTOR/FRAP is a member of the PIK-related 
family of protein kinases which contain a C-terminal lipid 
kinase domain, although no allied lipid kinase activity has 
been demonstrated yet for any member [31]. Despite the ob-
servation that mTOR/FRAP can autophosphorylate [30], oth-
er potential protein substrates remain elusive. It is still unclear 
whether mTOR/FRAP mediates its affects on p70s6k through 
its kinase domain or through binding an obligatory effector 
molecule. More importantly, given the intimate relationship 
between the effects of rapamycin on p70s6k through the N-
terminus of the kinase ([24,32,33] and below) it is critical to 
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Fig. 1. The putative effectors of p70s6k activity. Though the identification of the immediate upstream activators of p70s6k is still awaited, this 
scheme highlights the potential candidates, their effectors and, in certain cases their inhibitors referred to in this review, whose activities are 
speculated to culminate in the activation of p70s6k. 
establish the mechanism by which mTOR/FRAP activity is 
modulated in response to mitogens and whether dominant-
negative alleles of mTOR/FRAP actually interfere with the 
p70s6k input. 
Other pharmacological approaches have strongly indicated 
that a pathway leading to the activation of p70s6k is initiated 
by the recruitment of the phosphatidylinositide-3-kinase 
(PI-3K) to the activated receptor [34,35]. This enzyme 
phosphorylates the D-3 position of Ptdlns, PtdIns(4)P and 
PtdIns(4,5)P2 to produce second messengers which are 
thought to target a range of effector molecules [36], including 
the Rho family of G proteins [37], members of the novel and 
atypical PKCs [38,39] as well as the Ser/Thr kinase PKB/Akt 
[40-43]. Where mTOR/FRAP is located in this scheme is un-
clear (Fig. 1 and below). Constitutively active PI-3K alleles 
cause elevations in basal p70s6k activity [35,42], whereas wort-
mannin and the structurally unrelated LY294002 compound 
inhibit PI-3K as well as the activation of p70s6k in vivo 
[23,26,34,35,44]. However, not all the data from studies em-
ploying either receptor mutants [21] or dominant-negative 
molecules [45,46] are consistent with PI-3K activation being 
a necessary prerequisite for p70s6k activation. Furthermore, 
the specificity of wortmannin and LY294002 for PI-3K have 
been recently challenged [31,44,47], thus pharmacology is un-
likely to resolve this conflict and emphasises the need to iden-
tify the immediate effectors of p70s6k activation. 
PKB/Akt kinase, the insulin-responsive regulator of GSK-3 
[48], is recruited to the membrane in response to increasing 
levels of PtdIns(3,4)P2 [43]. Whilst PKB/Akt has not been 
shown to directly phosphorylate p70s6k, over-expression of a 
gag-fusion of PKB/Akt constitutively activates p70s6k [40]. 
More recently a PKB/Akt variant has been described which 
has acidic residues substituted at two key phosphorylation 
sites [49]. This mutant exhibits constitutive kinase activity 
and is resistant to wortmannin. If the wortmannin resistance 
of this mutant could be passed on to p70s6k and a dominant-
negative PKB/Akt could block p70s6k activation, this would 
be compelling support for placing PKB/Akt as an upstream 
regulator of p70s6k. TPA-induced activation of p70s6k is also 
not significantly inhibited by wortmannin [23], but since the 
effects of TPA and constitutively active PKB/Akt can be 
blocked by rapamycin treatment, the implication is that 
PKB/Akt and PKC are either further upstream of mTOR/ 
FRAP or reside on parallel pathways, signalling to a common 
component of the p70s6k pathway. 
Chou and Blenis [50] have shown that the small Rho family 
G proteins, rac-1 and cdc42, can bind in vitro to hypophos-
phorylated p70s6k in a GTP-dependent fashion and GTPase-
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Fig. 2. (A) A modular representation of p70s6k. The primary structure of p70s6k has been functionally dissected into four modules, indicated I-
IV below the figure. Identified sites of phosphorylation sites are indicated. (B) The modular activation of p70s6k. To generate p70s6k activity the 
critical sites in Module II, T229, and III, T389, must become phosphorylated. The four-step model presented here predicts that a functional in-
teraction between Modules I and IV is broken and stabilised (a), by phosphorylation of the S/T-P sites in Module IV (b). This event, possibly 
mediated by mTOR/FRAP, would allow the mitogen-activated T389 kinase to phosphorylate its critical cognate site in Module III, thereby al-
lowing the final T-loop phosphorylation at T229 (c), to propagate full kinase activity (d). 
deficient alleles elevate p70s6k activity in vivo. These are po-
tentially exciting observations, but it has yet to be resolved 
whether rac-l/cdc42 interact directly with p70s6k or if, instead, 
this event is dependent on a second molecule. The further 
troubling aspect of these studies is that the effect of activated 
alleles on p70s6k is blocked by wortmannin. This finding was 
rationalised by a model in which both rac-1 and PI-3K are 
required for p70s6k activation. The inference from this study is 
that, in the presence of active rac-1 alleles, basal levels of PI-
3K are sufficient to activate p70s6k. If this model is correct, 
then the ability of activated alleles of PI-3K, or PKB/Akt, to 
stimulate p70s6k should also be blocked by dominant-negative 
rac-1. 
3. The modular phosphorylation and activation of p70s6k 
The most significant advance in our understanding of p70s6k 
regulation will most likely be realised from focusing efforts on 
the identification of the kinases which directly activate the 
enzyme. A knowledge of the specific changes in the phospho-
rylation status of p70s6k and the mechanism by which they 
bring about kinase activation is a necessary corollary to this. 
In the absence of crystallographic data, structure/function 
relationships have been studied by the dissection of p70s6k 
primary structure into domains or modules (Fig. 2A). In brief, 
p70s6k can be roughly divided into four functionally significant 
modules. Module I extends from the N-terminus to the begin-
ning of the catalytic domain and confers rapamycin sensitivity 
to p70s6k [24,32,33]. Module II contains the conserved cata-
lytic domain, including the acute site of mitogen-induced 
phosphorylation in the activation T-loop [27,35]. Module III 
links the catalytic domain with the carboxyl tail, contains two 
additional sites of acute phosphorylation and is conserved in 
many members of the second messenger family of Ser/Thr 
kinases [27]. Finally, Module IV contains the putative auto-
inhibitory domain, which has significant homology with the 
substrate region of S6, and four closely clustered phosphor-
ylation sites [22]. p70s6k activation by interactions of each of 
these modules has manifested itself as a hierarchy of interde-
pendent phosphorylation events. Seven sites of phosphoryla-
tion have been identified in the endogenous enzyme (Fig. 2A), 
with a further five either confirmed or predicted through stud-
ies employing ectopically expressed kinase. The initially iden-
tified sites of phosphorylation, S411, S418, T421 and S424 are 
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all flanked by a proline in the +1 position and reside within 
the putative autoinhibitory domain of Module IV [22]. Pep-
tides which correspond in sequence to this domain inhibit the 
kinase [51], consistent with the hypothesis that Module IV 
acts as an autoinhibitory domain. These four residues are 
hypophosphorylated in quiescent cells, and become hyper-
phosphorylated in response to serum [23]. Substitution of 
these S/T-P sites with alanines [23] suppresses activation of 
the kinase, whilst the corresponding acidic residue replace-
ments raise basal kinase activity [10]. However, full kinase 
activation is accompanied by the acute phosphorylation of 
T229, in the T-loop, as well as T389 and S404 in Module 
III [23,27]. The distance between T389 and T229 is conserved 
in other kinases of the second messenger family that contain 
these homologous sites [27]. These residues are characteristi-
cally flanked by bulky aromatic residues; the sequence simi-
larity extends throughout Module III, suggesting that this 
module may play a role as a general regulator of kinase ac-
tivity in those kinases which contain these motifs. 
Although T229 phosphorylation is critical in modulating 
kinase activity of p70s6k [27,35] and other mitogen-activated 
kinases, several lines of evidence indicate that T389 phospho-
rylation is the chief event through which full p70s6k activity is 
acceded. Firstly, although the inhibitory effects of rapamycin 
and wortmannin are exerted through the dephosphorylation 
of T229, T389 and S404 [23,27], the principal target is T389 
[27,33]. The effects of these drugs on p70s6k can be suppressed 
by a T389E change, whereas a T389A substitution fully in-
activates p70s6k [27]. Emerging data from this laboratory in-
dicate that T389 phosphorylation modulates p70s6k activation 
through alterations in T229 phosphorylation (P.B. Dennis, N. 
Pullen and G. Thomas, unpublished). A T389E substitution 
elevates T229 phosphorylation, whereas T389A blocks it. 
T229 mutations to alanine or glutamic acid ablate kinase ac-
tivity and do not potentiate T389 phosphorylation [27]. Thus 
a simple picture of p70s6k activation is one in which T389 
phosphorylation regulates T229 phosphorylation in a coordi-
nated and hierarchical fashion. It has been suggested that PI-
3K may directly modulate the phosphorylation of T229 and 
p70s6k activation [35]. However, recent studies from this labo-
ratory employing activated alleles of PI-3K and a construct 
lacking Modules I and II, p70s6kAN54ACio4, demonstrate that 
these effects, as previously shown with serum [33], are medi-
ated by T389 phosphorylation (N. Pullen and G. Thomas, 
unpublished). 
How then do these phosphorylation sites and modules in-
teract with one another to bring about p70s6k activation? Re-
cent studies from Avruch and collaborators [24] have demon-
strated that removal of Module I severely impairs the ability 
of the kinase to be activated by mitogens. This deficiency also 
prevented mitogens from inducing T229 and T389 phospho-
rylation [33]. The effect of Module I truncation on activity can 
be rescued by removal of Module IV [24,32,33] or by simply 
replacing the S/T-P sites in this module with acidic residues 
(P.B. Dennis, N. Pullen and G. Thomas, unpublished). In 
both instances, the recovery in activity is accompanied by 
T229 and T389 phosphorylation [27,33]. Truncation of Mod-
ule IV alone does not significantly effect basal kinase levels, 
whereas substitution of acidic residues in the S/T-P positions 
do [10,27]. Collectively, these data suggest Modules I and IV 
cooperate in signalling to T389 (Fig. 2B). The surprising ob-
servation that the p70s6kAN54ACio4 construct was resistant to 
the effects of rapamycin, whilst retaining wortmannin sensi-
tivity [24,32,33], casts some doubt on the role of phosphoryl-
ation in governing p70s6k activation. In the absence of serum, 
this construct had high basal T229 phosphorylation [33], but 
low T389 phosphorylation and low kinase activity. Full kinase 
activity was accompanied by T389 phosphorylation, in re-
sponse to serum, and the phosphorylation of T229 and 
T389 was fully protected in the presence of rapamycin [33]. 
This is in stark contrast to the behaviour of the wild type 
enzyme and made it difficult to rationalise mTOR/FRAP as 
the progenitor of either T389 or T229 kinase activity per se. 
Instead, if linked with p70s6k activation, mTOR/FRAP must 
mobilise the interaction between Modules I and IV for func-
tion. This further raises the significance of Module IV in 
modulating kinase activity by, firstly, regulating access to 
T389 and, secondly, by restricting the access to T229 until 
T389 is phosphorylated (Fig. 2B). We [33] and others [24,32] 
have speculated that removal of the N-terminus prevents an 
effector molecule from binding, an event which is possibly 
mediated by mTOR/FRAP and necessary for transducing 
the mitogenic signal through Module IV to T389 phospho-
rylation (Fig. 2B). In contrast to rapamycin, phosphorylation 
of T389 in the p70s6kAN54ACio4 mutant was completely abol-
ished by wortmannin. Although kinase activity was ablated, 
under these conditions, T229 phosphorylation was unaffected 
[33]. Since full kinase activity, apparently, requires phospho-
rylation of T229 and T389, the identification of the kinases 
which mediate these phosphorylation events is clearly impor-
tant. Nevertheless, the implications of these data are that 
T229 kinase activity is unregulated in vivo and only depend-
ent on T389 phosphorylation (Fig. 2B), suggesting that un-
masking upstream signalling elements will be best served by 
identifying the kinases which phosphorylate T389 and the S/ 
T-P sites. 
As described in Fig. 2B, the tentative model of p70s6k acti-
vation is presently thought to proceed by the binding of an 
effector molecule at the N-terminus which segregates it from 
the C-terminus. Hyperphosphorylation of the S/T-P sites in 
Module IV are thought to stabilise this interaction, allowing a 
mitogen-regulated kinase to phosphorylate T389 and, in turn, 
propagate phosphorylation of the T-loop site leading to full 
activity. With increased understanding of how each phospho-
rylation event can be transmitted to another, this should en-
courage workers to utilise this information in designing ex-
periments which will ultimately assign names and faces to the 
kinases, phosphatases and effectors of the signalling pathway 
to p70s6k. 
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